Skip to main content
SpringerLink
Log in

Current Status of Diagnostic and Prognostic Markers in Melanoma

  • Protocol
  • First Online:
Molecular Diagnostics for Melanoma

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1102))

Abstract

Melanoma is the most life-threatening common form of skin cancer. While most cutaneous melanomas are cured by surgical resection, a minority will relapse locally, regionally, or distantly. Biomarkers have represented a focal point for research aimed at improving diagnostic accuracy as well as providing prognostic information that may help to guide therapeutic decisions. While systemic melanoma therapies were of extremely limited utility for patients with advanced disease in the past, two drugs have been approved the FDA within the past several years, and it is possible that they may provide even greater impact if employed earlier in the disease process. To optimally employ these therapies, prognostic biomarkers may offer significant value. This article reviews methodologies for both discovery and routine testing of melanoma biomarkers. It also focuses on specific commonly used markers, as well as approaches to studying their applications to specific clinical settings. As the armamentarium of melanoma drugs grows, it is hoped that specific biomarkers will aid in guiding the use of these agents for patients in the clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249

    Article  PubMed  Google Scholar 

  2. Ak I, Stokkel MP, Bergman W, Pauwels EK (2000) Cutaneous malignant melanoma: clinical aspects, imaging modalities and treatment. Eur J Nucl Med 27:447–458

    Article  PubMed  CAS  Google Scholar 

  3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199–6206

    Article  PubMed  Google Scholar 

  4. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U et al (2007) Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 17:393–399

    Article  PubMed  Google Scholar 

  5. Bishop JA, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N et al (2002) UK guidelines for the management of cutaneous melanoma. Br J Plast Surg 55:46–54

    Article  PubMed  CAS  Google Scholar 

  6. Dummer R, Hauschild A (2008) Jost L Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2):ii86–ii88

    Article  PubMed  Google Scholar 

  7. Francken AB, Accortt NA, Shaw HM, Colman MH, Wiener M, Soong SJ et al (2008) Follow-up schedules after treatment for malignant melanoma. Br J Surg 95:1401–1407

    Article  PubMed  CAS  Google Scholar 

  8. Sabel MS, Liu Y, Lubman DM (2011) Proteomics in melanoma biomarker discovery: great potential, many obstacles. Int J Proteomics 2011:181890

    PubMed  Google Scholar 

  9. Shi SR, Liu C, Taylor CR (2007) Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis. J Histochem Cytochem 55(2):105–109

    Article  PubMed  CAS  Google Scholar 

  10. Coons AH (1791) The development of immunohistochemistry. NY Acad Sci 177:5–9

    Google Scholar 

  11. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844–847

    Article  PubMed  CAS  Google Scholar 

  12. Battifora H, Skacel M, Skilton B, Pettay JD, Tubbs RR (2002) Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens. Appl Immunohistochem Mol Morphol 10:1–6

    Google Scholar 

  13. Horne BD, Carlquist JF, Cannon-Albright LA, Muhlestein JB, McKinney JT, Kolek MJ, Clarke JL, Anderson JL, Camp NJ (2006) High-resolution characterization of linkage disequilibrium structure and selection of tagging single nucleotide polymorphisms: application to the cholesteryl ester transfer protein gene. Ann Hum Genet 70(Pt 4):524–534

    Article  PubMed  CAS  Google Scholar 

  14. Marvin LF, Roberts MA, Fay LB (2003) Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in clinical chemistry. Clin Chim Acta 337(1–2):11–21

    Article  PubMed  CAS  Google Scholar 

  15. de Vries TJ, Smeets M, de Graaf R, Hou-Jensen K, Bröcker EB, Renard N, Eggermont AM, van Muijen GN, Ruiter DJ (2001) Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol 193(1):13–20

    Article  PubMed  Google Scholar 

  16. Utikal J, Schadendorf D, Ugurel S (2007) Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res 298(10):469–477

    Article  PubMed  CAS  Google Scholar 

  17. Gogas H, Eggermont AM, Hauschild A, Hersey P, Mohr P, Schadendorf D, Spatz A, Dummer R (2009) Biomarkers in melanoma. Ann Oncol 20(Suppl 6):vi8–vi13

    Article  PubMed  Google Scholar 

  18. Liu S, Kirschmeier P, Simon J, Seidel-Dugan C, Puhlmann M (2008) Prognostic and predictive molecular markers in cutaneous malignant melanoma: the first step toward personalized medicine. Curr Pharmacogenomics Person Med 6(4):272–294

    Article  Google Scholar 

  19. Deichmann M, Benner A, Bock M, Jäckel A, Uhl K, Waldmann V, Näher H (1999) S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17(6):1891–1896

    PubMed  CAS  Google Scholar 

  20. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kashani-Sabet M, Lange JR, Lind A, Martin L, Martini MC, Pruitt SK, Ross MI, Sener SF, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, Weber J, Wong MK, NCCN melanoma panel (2009) Melanoma. J Natl Compr Canc Netw 7(3):250–275

    PubMed  CAS  Google Scholar 

  21. Thompson JF, Shaw HM, Stretch JR, McCarthy WH, Milton GW (2003) The Sydney melanoma unit—a multidisciplinary melanoma treatment center. Surg Clin North Am 83(2):431–451

    Article  PubMed  Google Scholar 

  22. Deichmann M, Kahle B, Moser K, Wacker J, Wüst K (2004) Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer 91(4):699–702

    PubMed  CAS  Google Scholar 

  23. Moore Dalal K, Zhou Q, Panageas KS, Brady MS, Jaques DP, Coit DG (2008) Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol 15(8):2206–2214

    Article  PubMed  Google Scholar 

  24. Lin J, Yang Q, Wilder PT, Carrier F, Weber DJ (2010) The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J Biol Chem 285(35):27487–27498

    Article  PubMed  CAS  Google Scholar 

  25. Kruijff S, Hoekstra HJ (2012) The current status of S-100B as a biomarker in melanoma. Eur J Surg Oncol 38(4):281–285

    Article  PubMed  CAS  Google Scholar 

  26. Bouwhuis MG, Suciu S, Kruit W, Salès F, Stoitchkov K, Patel P, Cocquyt V, Thomas J, Liénard D, Eggermont AM, Ghanem G (2011) Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952. European Organisation for Research and Treatment of Cancer Melanoma Group. Eur J Cancer 47(3):361–368

    Article  PubMed  CAS  Google Scholar 

  27. Vereecken P, Cornelis F, Van Baren N, Vandersleyen V, Baurain JF (2012) A synopsis of serum biomarkers in cutaneous melanoma patients. Dermatol Res Pract 2012:260643

    Google Scholar 

  28. Dummer R, Panizzon R, Bloch PH, Burg G (2005) Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 210(1):39–44

    Article  PubMed  CAS  Google Scholar 

  29. Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R, Hauschild A (2008) Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges 6(Suppl 1):S9–S14

    PubMed  Google Scholar 

  30. Retsas S, Mastrangelo MJ (2007) Reflecting on the 2001 American Joint Committee on Cancer Staging System for melanoma. Semin Oncol 34(6):491–497

    Article  PubMed  Google Scholar 

  31. Vihinen PP, Hilli J, Vuoristo MS, Syrjänen KJ, Kähäri VM, Pyrhönen SO (2007) Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta Oncol 46(5):678–684

    Article  PubMed  CAS  Google Scholar 

  32. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE (2007) Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13(8):2422–2428

    Article  PubMed  CAS  Google Scholar 

  33. Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM (2010) Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 41(3):375–384, Epub 2009 Dec 11

    Article  PubMed  CAS  Google Scholar 

  34. Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Comessatti MG (2002) VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res 12(4):325–334

    Article  PubMed  CAS  Google Scholar 

  35. Väisänen A, Kuvaja P, Kallioinen M, Turpeenniemi-Hujanen T (2011) A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Hum Pathol 42(8):1103–1111

    Article  PubMed  Google Scholar 

  36. Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, Sznol M, Ariyan S, Molinaro A, Halaban R (2011) Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res 17(8):2417–2425

    Article  PubMed  CAS  Google Scholar 

  37. Bu W, Tang ZY, Sun FX, Ye SL, Liu KD, Xue Q, Chen J, Gao DM (1998) Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepatogas-troenterology 45(22):1056–1061

    Google Scholar 

  38. Rey MC, Bonamigo RR, Cartell A, Furian R, Bonfá R, Bonfá R (2011) MMP-2 and TIMP-2 in cutaneous melanoma: association with prognostic factors and description in cutaneous metastases. Am J Dermatopathol 33(4):413–414

    Article  PubMed  Google Scholar 

  39. Kurschat P, Wickenhauser C, Groth W, Krieg T, Mauch C (2002) Identification of activated matrix metalloproteinase-2 (MMP-2) as the main gelatinolytic enzyme in malignant melanoma by in situ zymography. J Pathol 197(2):179–187

    Article  PubMed  CAS  Google Scholar 

  40. Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D (2000) Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 20(3B):2203–2207

    PubMed  CAS  Google Scholar 

  41. Bougatef F, Menashi S, Khayati F, Naïmi B, Porcher R, Podgorniak MP, Millot G, Janin A, Calvo F, Lebbé C, Mourah S (2010) EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2. PLoS One 5(8):e12265

    Article  PubMed  Google Scholar 

  42. Kanekura T, Chen X (2010) CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci 57(3):149–154

    Article  PubMed  CAS  Google Scholar 

  43. van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C (1997) Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 151(3):665–670

    PubMed  Google Scholar 

  44. Wang YG, Kim SJ, Baek JH, Lee HW, Jeong SY, Chun KH (2012) Galectin-3 increases the motility of mouse melanoma cells by regulating MMP-1 expression. Exp Mol Med 44(6):387–393

    Article  PubMed  CAS  Google Scholar 

  45. Chen T, Zhu J (2010) Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma. Med Oncol 27(4):1185–1191

    Article  PubMed  CAS  Google Scholar 

  46. Guida M, Riccobon A, Biasco G, Ravaioli A, Casamassima A, Freschi A, Palma MD, Galligioni E, Nortilli R, Chiarion-Sileni V, Picozzo J, Romanini A, Nanni O, Ridolfi R, Italian Melanoma Intergroup (IMI) (2006) Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. Melanoma Res 16(4):317–323

    Article  PubMed  CAS  Google Scholar 

  47. Boyano MD, Garcia-Vázquez MD, López-Michelena T, Gardeazabal J, Bilbao J, Cañavate ML, Galdeano AG, Izu R, Díaz-Ramón L, Raton JA, Díaz-Pérez JL (2000) Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 83(7):847–852

    Article  PubMed  CAS  Google Scholar 

  48. Vuoristo MS, Laine S, Huhtala H, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E, Kellokumpu-Lehtinen P (2001) Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer 37(13):1629–1634

    Article  PubMed  CAS  Google Scholar 

  49. Alonso SR, Ortiz P, Pollán M, Pérez-Gómez B, Sánchez L, Acuña MJ, Pajares R, Martínez-Tello FJ, Hortelano CM, Piris MA, Rodríguez-Peralto JL (2004) Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 164(1):193–203

    Article  PubMed  CAS  Google Scholar 

  50. de Souza CF, Morais AS, Jasiulionis MG (2012) Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract 2012:156068. Epub 2011 Oct 31

    Google Scholar 

  51. Gould Rothberg BE, Bracken MB, Rimm DL (2009) Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 101(7):452–474

    Article  PubMed  Google Scholar 

  52. Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R (2001) Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol 195(5):530–536

    Article  PubMed  CAS  Google Scholar 

  53. Niezabitowski A, Czajecki K, Rys J (1999) Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol 70(3):150–160

    Article  PubMed  CAS  Google Scholar 

  54. Duncan LM, Deeds J, Hunter J, Shao J, Holmgren LM, Woolf EA, Tepper RI, Shyjan AW (1998) Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 58:1515

    PubMed  CAS  Google Scholar 

  55. Deeds J, Cronin F, Duncan LM (2000) Patterns of melastatin mRNA expression in melanocytic tumors. Hum Pathol 31:1346

    Article  PubMed  CAS  Google Scholar 

  56. Erickson LA, Letts GA, Shah SM, Shackelton JB, Duncan LM (2009) TRPM1 (Melastatin-1/MLSN1) mRNA expression in Spitz nevi and nodular melanomas. Mod Pathol 22(7):969–976

    Article  PubMed  CAS  Google Scholar 

  57. Duncan LM, Deeds J, Cronin FE, Donovan M, Sober AJ, Kauffman M, McCarthy JJ (2001) Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 19:568–576

    PubMed  CAS  Google Scholar 

  58. Miller AJ, Du J, Rowan S, Hershey CL, Widlund HR, Fisher DE (2004) Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res 64:509

    Article  PubMed  CAS  Google Scholar 

  59. Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, Valgeirsdottir S, Bergsteinsdottir K, Schepsky A, Dummer R, Steingrimsson E (2008) Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res 21:665

    Article  PubMed  CAS  Google Scholar 

  60. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117–122

    Article  PubMed  CAS  Google Scholar 

  61. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR, Fisher DE (2004) Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6:565–576

    Article  PubMed  CAS  Google Scholar 

  62. Yokoyama S, Woods SL, Boyle GM, Aoude LG, MacGregor S, Zismann V, Gartside M, Cust AE, Haq R, Harland M, Taylor JC, Duffy DL, Holohan K, Dutton-Regester K, Palmer JM, Bonazzi V, Stark MS, Symmons J, Law MH, Schmidt C, Lanagan C, O’Connor L, Holland EA, Schmid H, Maskiell JA, Jetann J, Ferguson M, Jenkins MA, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Whiteman DC, Pharoah PD, Easton DF, Dunning AM, Newton-Bishop JA, Montgomery GW, Martin NG, Mann GJ, Bishop DT, Tsao H, Trent JM, Fisher DE, Hayward NK, Brown KM (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480:99–103

    Article  PubMed  CAS  Google Scholar 

  63. Flaherty KT, Hodi FS, Fisher DE (2012) From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12(5):349–361

    Article  PubMed  CAS  Google Scholar 

  64. Hillesheim PB, Slone S, Kelley D, Malone J, Bahrami S (2011) An immunohistochemical comparison between MiTF and MART-1 with Azure blue counterstaining in the setting of solar lentigo and melanoma in situ. J Cutan Pathol 38(7):565–569

    Article  PubMed  Google Scholar 

  65. Nielsen PS, Riber-Hansen R, Steiniche T (2011) Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions. Am J Dermatopathol 33(4):361–370

    Article  PubMed  Google Scholar 

  66. Samija I, Lukac J, Marić-Brozić J, Buljan M, Alajbeg I, Kovacević D, Situm M, Kusić Z (2010) Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma. Melanoma Res 20(4):293–302

    Article  PubMed  CAS  Google Scholar 

  67. Bosserhoff AK, Hein R, Bogdahn U, Buettner R (1996) Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 271(1):490–495

    Article  PubMed  CAS  Google Scholar 

  68. Garnier JP, Letellier S, Cassinat B, Lebbé C, Kerob D, Baccard M, Morel P, Basset-Seguin N, Dubertret L, Bousquet B, Stoitchkov K, Le Bricon T (2007) Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer 43(4):816–821

    Article  PubMed  CAS  Google Scholar 

  69. Díaz-Lagares A, Alegre E, Arroyo A, González-Cao M, Zudaire ME, Viteri S, Martín-Algarra S, González A (2011) Evaluation of multiple serum markers in advanced melanoma. Tumour Biol 32(6):1155–1161

    Article  PubMed  Google Scholar 

  70. Nakahara S, Oka N, Raz A (2005) On the role of galectin-3 in cancer apoptosis. Apoptosis 10(2):267–275

    Article  PubMed  CAS  Google Scholar 

  71. Brown ER, Doig T, Anderson N, Brenn T, Doherty V, Xu Y, Bartlett JM, Smyth JF, Melton DW (2012) Association of galectin-3 expression with melanoma progression and prognosis. Eur J Cancer 48(6):865–874

    Article  PubMed  CAS  Google Scholar 

  72. Buljan M, Šitum M, Tomas D, Milošević M, Krušlin B (2011) Prognostic value of galectin-3 in primary cutaneous melanoma. J Eur Acad Dermatol Venereol 25(10):1174–1181

    Article  PubMed  CAS  Google Scholar 

  73. Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M (2008) Osteopontin as a molecular prognostic marker for melanoma. Cancer 112(1):144–150

    Article  PubMed  Google Scholar 

  74. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR (2007) Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20(1):102–107

    Article  PubMed  CAS  Google Scholar 

  75. Ebrahimnejad A, Streichert T, Nollau P, Horst AK, Wagener C, Bamberger AM, Brümmer J (2004) CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol 165(5):1781–1787

    Article  PubMed  CAS  Google Scholar 

  76. Thies A, Moll I, Berger J, Wagener C, Brümmer J, Schulze HJ, Brunner G, Schumacher U (2002) CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 20(10):2530–2536

    Article  PubMed  CAS  Google Scholar 

  77. Watson-Hurst K, Becker D (2006) The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion. Cancer Biol Ther 5(10):1375–1382

    Article  PubMed  CAS  Google Scholar 

  78. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson G (2005) Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 115(2):367–375

    Article  PubMed  CAS  Google Scholar 

  79. Kärnell R, Kågedal B, Lindholm C, Nilsson B, Arstrand K, Ringborg U (2000) The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma Res 10(4):363–369

    Article  PubMed  Google Scholar 

  80. Kvam E, Dahle J (2005) The pheomelanin precursor 5-S-cysteinyldopa protects melanocytes from membrane damage induced by ultraviolet A radiation. Cancer Lett 221(2):131–134

    Article  PubMed  CAS  Google Scholar 

  81. Bánfalvi T, Boldizsár M, Gergye M, Gilde K, Kremmer T, Ottó S (2002) Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma. Pathol Oncol Res 8(3):183–187

    Article  PubMed  Google Scholar 

  82. Slominski A, Zmijewski MA, Pawelek J (2012) L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res 25(1):14–27

    Article  PubMed  CAS  Google Scholar 

  83. Abaffy T, Duncan R, Riemer DD, Tietje O, Elgart G, Milikowski C, DeFazio RA (2010) Differential volatile signatures from skin, naevi and melanoma: a novel approach to detect a pathological process. PLoS One 5(11):e13813

    Article  PubMed  Google Scholar 

  84. Greenberg ES, Chong KK, Huynh KT, Tanaka R, Hoon DS (2012) Epigenetic biomarkers in skin cancer. Cancer Lett

    Google Scholar 

  85. Nguyen T, Kuo C, Nicholl MB, Sim MS, Turner RR, Morton DL, Hoon DS (2011) Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 6(3):388–394

    Article  PubMed  CAS  Google Scholar 

  86. McShane LM, Altman DG, Gion M, Clark GM, Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics (2006) Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229–235

    Article  PubMed  Google Scholar 

  87. Schramm SJ, Mann GJ (2011) Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther 10(8):1520–1528, Epub 2011 Jun 9. Review

    Article  PubMed  CAS  Google Scholar 

  88. Pras F, Perra MT, Murtas D, Minerba L, Floris C, Maxia C (2008) Combinations of apoptosis and cell-cycle control biomarkers predict the outcome of human melanoma. Oncol Rep 20:271–277

    Google Scholar 

  89. Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F (2009) A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 15:6987–6992

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA

    Danielle Levine & David E. Fisher

Authors
  1. Danielle Levine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David E. Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cancer Diagnosis Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

    Magdalena Thurin

  2. Sidra Medical and Research Center,Qatar Foundation, Doha, Qatar

    Francesco M. Marincola

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media, New York

About this protocol

Cite this protocol

Levine, D., Fisher, D.E. (2014). Current Status of Diagnostic and Prognostic Markers in Melanoma. In: Thurin, M., Marincola, F. (eds) Molecular Diagnostics for Melanoma. Methods in Molecular Biology, vol 1102. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-727-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-727-3_11

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-726-6

  • Online ISBN: 978-1-62703-727-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation